Comparison
Berberine vs GHRP-2
Side-by-side of Berberine and GHRP-2. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Berberine
Berberine supplement guide: 1500 mg/day lowers fasting glucose and HbA1c, AMPK activation, metformin parity in RCTs, dihydroberberine absorption.
GHRP-2
GHRP-2 peptide (pralmorelin, KP-102) is a synthetic hexapeptide ghrelin-receptor agonist that triggers pulsatile growth hormone release via the pituitary.
Effects at a glance
Berberine
- •Lowers HbA1c by ~0.7% versus placebo at 1500 mg/day across 27-trial meta-analysis (Lan 2015)
- •Roughly comparable to metformin on fasting glucose and HbA1c in small head-to-head RCTs (Yin 2008)
- •Reduces LDL cholesterol 10-20% and triglycerides 15-25% via PCSK9 inhibition
- •Activates AMPK, the cellular energy sensor that drives insulin-independent glucose uptake
- •Oral bioavailability under 1%; dihydroberberine is the higher-absorption alternative at lower doses
- •GI side effects affect 10-30% at 1500 mg/day; split dosing with meals reduces incidence
GHRP-2
- •Hexapeptide ghrelin-receptor agonist that stimulates pulsatile GH release within 15 to 30 minutes
- •Strongest appetite signal among GHRPs at standard doses; centrally mediated via NPY/AgRP
- •Produces measurable cortisol and prolactin rise (more than ipamorelin, less than GHRP-6)
- •Approved in Japan as pralmorelin for GH-deficiency diagnostic provocation; not FDA approved
- •Anecdotal protocols use 100 to 300 mcg subcutaneously 2 to 3 times daily on an empty stomach
- •Banned by WADA under S2; detection methods validated in accredited labs
Side-by-side
| Attribute | Berberine | GHRP-2 |
|---|---|---|
| Category | natural | peptide |
| Also known as | berberine HCl, berberine hydrochloride | Growth Hormone Releasing Peptide 2, Pralmorelin, KP-102, GPA-748 |
| Half-life (hr) ↗ | 3 | 0.5 |
| Typical dose (mg) ↗ | 1500 | 0.1 |
| Dosing frequency | 3x daily with meals | 2-3x daily |
| Routes | oral | subcutaneous, intranasal, intravenous |
| Onset (hr) | 2 | 0.25 |
| Peak (hr) | 3 | 0.5 |
| Molecular weight | 336.36 | 817.97 |
| Molecular formula | C20H18NO4+ | C45H55N9O6 |
| Mechanism | Activates AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and lipogenesis while increasing peripheral glucose uptake. Inhibits PCSK9 transcription, modulates bile acid signaling, and shifts gut microbiome composition. | Hexapeptide agonist of the growth-hormone secretagogue receptor (GHS-R1a). Suppresses hypothalamic somatostatin tone and stimulates pituitary somatotrophs, producing a pulsatile GH release with secondary cortisol, prolactin, and ACTH elevation. |
| Legal status | Dietary supplement (US, EU, UK, Canada); Rx in some Asian jurisdictions | Not FDA approved; approved in Japan as pralmorelin (diagnostic); research-use-only grey market in US/EU; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | Not scheduled | Not scheduled in US (research chemical); approved diagnostic in Japan |
| Pregnancy | Contraindicated (kernicterus risk in neonates) | Insufficient data; not recommended |
| CAS | 2086-83-1 | 158861-67-7 |
| PubChem CID | 2353 | 9919072 |
| Wikidata | Q411435 | Q7235681 |
Safety profile
Berberine
Common side effects
- constipation
- diarrhea
- abdominal cramping
- flatulence
- nausea
Contraindications
- pregnancy
- lactation
- neonatal jaundice
- severe liver disease
Interactions
- metformin: additive HbA1c reduction; additive GI side effects(moderate)
- insulin or sulfonylureas: additive hypoglycemia risk; dose adjustment may be required(major)
- statins (simvastatin, atorvastatin): CYP3A4 inhibition raises statin plasma levels(moderate)
- cyclosporine: raises cyclosporine levels through CYP3A4 and P-gp inhibition(major)
- calcium channel blockers (amlodipine): elevated plasma levels via CYP3A4 inhibition(moderate)
GHRP-2
Common side effects
- acute hunger
- head pressure or flushing
- water retention
- vivid dreams
- tingling at injection site
- transient lethargy
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- severe insulin resistance
Interactions
- CJC-1295: synergistic GH release; commonly co-administered for larger pulse(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response and amplify cortisol load(moderate)
Which Should You Take?
Berberine comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. GHRP-2 is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Berberine.
- → If your priority is healthspan extension, pick Berberine.
- → If your priority is growth-hormone axis, pick GHRP-2.
- → If your priority is post-training recovery, pick GHRP-2.
Edge case: If you want to avoid research-only / gray-market sourcing, Berberine is the more accessible choice.
Default choice: Berberine. Lower friction to source, and broader goal coverage. Reach for GHRP-2 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Berberine and GHRP-2?
Berberine and GHRP-2 differ in category (natural vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Berberine or GHRP-2?
Berberine half-life is 3 hours; GHRP-2 half-life is 0.5 hours.
Can you stack Berberine with GHRP-2?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper